PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION

Aim: cost-effectiveness assessment and budget impact analysis for 13-valent pneumococcal conjugate vaccine (PCV13) in infant immunization program in Russian Federation. Materials and methods: 10 year modeling with social perspective (direct medical and indirect costs and life expectancy with discounting by 3,5% per year) and population effect based on results of clinical studies, global PCV13 use and Russian epidemiological data has been established. Budget impact has been analyzed without discounting. Direct effect was assessed by influence on pneumococcal meningitis, bacteremia, pneumonia and acute otitis media (AOM) incidence, population effect — by pneumococcal meningitis and hospitalized all-cause pneumonia incidence. Results: Possible PCV13 effectiveness was estimated as 76,6% for invasive pneumococcal diseases (IPD) and 23,7% for hospitalized cases of AOM. Vaccination (per 100 000 vaccinated infants) can prevent 13,8 lethal cases in vaccinated population and 171,1 — in unvaccinated population. Cost-effectiveness ratio for PCV13 is estimated as 32,400 rubles / LYG and 32,400 rubles / QALY. Cost of 1 lethal case prevention is 140 100 rubles, additional cost for 10 years is 111,5 rubles per child. Conclusions: PCV13 mass vaccination of infants in Russian Federation is highly cost-effective and will significantly cut expenses due to pneumococcal diseases treatment.

1. Koroleva I.S., Beloshitskii G.V. Epidemiological characteristics of pneumococcal meningitis in children under the age of 6 years in the Russian Federation. Epidemiol. i inf. bol. = Epidemiology and infectious diseases. 2012; 1: 18–21.

2. Foster D., Knox K., Walker A. et al. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J. Med. Microbiol. 2008; 57: 480–487.

3. Vergison A., Tuerlinckx D., Verhaegen J., Malfroot A. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics. 2006; 118: 801.

4. Rendi-Wagner P., Georgopoulos A., Kundi M. et al. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria. J. Antimicrob. Chemother. 2004; 53: 826–831.

5. Baranov A.A., Briko N.I., Namazova-Baranova L.S. Modern clinical and epidemiological characteristics of pneumococcal infections. Lechashchii vrach – Practicing doctor. 2012; 4.

6. Vengerov Yu.Ya., Nagibina M.V., Mikhalinova E.P. et al. Pneumococcal meningitis. The problem of high mortality. Lechashchii vrach = Practicing doctor. 2013; 5.

7. Klok R.M., Lindkvist R.-M., Ekelund M. et al. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin. Ther. 2013; http://dx.doi.org/10.1016/j.clinthera.2012.12.006.

8. Tatochenko V.K. Pneumococcal infection is a vaccine-preventable disease now. Zh. Mikrobiol. Epidemiol. Immunobiol. 2010; 3: 102–108.

9. Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka. Federal'nyi tsentr gigieny i epidemiologii. Svedeniya ob infektsionnykh i parazitarnykh zabolevaniyakh (Forma 2). Infektsionnye zabolevaniya za 2012 g [The Federal Service for Supervision of Consumer Rights Protection and Human Welfare. Federal Center of Hygiene and Epidemiology. Information on Infectious and Parasitic Diseases (Form 2). Infectious Diseases in 2012].

10. Vnebol'nichnaya pnevmoniya u detei: rasprostranennost', diagnostika, lechenie i profilaktika. Nauch.-prakt. progr. Rossiiskoe respiratornoe obshchestvo, Federatsiya pediatrov stran SNG, Moskovskoe obshchestvo detskikh vrachei [Community-acquired Pneumonia in Children: Prevalence, Diagnosis, Treatment and Prevention. Scientific and Practical. Prog. Russian Respiratory Society, the Federation of CIS Pediatricians, Moscow Society of Pediatricians]. Moscow, 2011. 63 p.

11. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S., Tyurin I.E., Rachina S.A. Vnebol'nichnaya pnevmoniya u vzroslykh: prakt. rekomendats. po diagnostike, lecheniyu i profilaktike. Pos. dlya vrachei [Community-acquired Pneumonia in Adults: Pract. Recommendations, Diagnosis, Treatment and Prevention. Guideline]. Moscow, 2010. 106 p.

12. Plasschaert A., Rovers M., Schilder A. et al. Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children. 1995–2003. Pediatrics. 2006; 117: 1879–1886.

13. Kozlov R. S., Krechikova O. I., Murav'ev A. A. et al. he results of the Russian studies of the prevalence of community-acquired pneumonia and acute otitis media in children aged up to 5 years (PAPIRUS), and the role of S. pneumoniae and H . influenzae in the etiology of these diseases. Klin. mikrobiol. i antimikrobn. khimioter. = Clinical microbiology and antimicrobial chemotherapy. 2013; 15 (4): 246–260.

14. Rozenbaum M., Sanders E., van Hoek A. et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010; 340: 2509. Doi:10.1136/bmj.c2509

15. Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads//slides-oct-2013/02-Pneumococcal-Moore.pdf

16. Pneumococcal vaccines. WHO position paper –2012. Weekly Epidemiol. Rec. 2012; 87: 129–144.

17. Lobzin Yu.V., Sidorenko S.V., Kharit S.M. et al. Serotypes Streptococcus pneumoniae, the leading cause nosological forms of pneumococcal infections.. Zhurn. infektol. = Infectology journal. 2013; in print.

18. Mayanskii N.A., Alyab'eva N.M., Ivanenko A.M. et al. The bacterial etiology of acute otitis media in children under 5 years: the role of Streptococcus pneumoniae. Vopr. diagnostiki v pediatrii = Diagnostics in pediatrics. 2013; 5 (3): 5–13.

19. Baranov A.A., Namazova-Baranova L.S., Mayanskii N.A. et al. The role of Streptococcus pneumoniae in the structure of bacterial infections in children admitted to hospitals in Moscow in 2011-2012. Pediatrich. farmakol. = Pediatric pharmacology. 2013; 10 (5): 6–12.

20. Fletcher M.A., Fritzell B. Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int. J. Otolaryngol. 2012: 312935.

21. Griffin M., Zhu Y., Moore M. et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N. Engl. J. Med. 2013; 369: 155–163.

22. Hortal, M. et al. Hospitalized children with pneumonia in Uruguay: Pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine. 2012; 30 (33):4934–4938.

23. Strutton D., Farkouh R., Earnshaw S. et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J. Inf. 2012; 64: 54–67.

24. Prilozheniya k General'nomu tarifnomu soglasheniyu po tarifam na meditsinskuyu pomoshch' (meditsinskie uslugi) i usloviyam oplaty meditsinskoi pomoshchi, okazyvaemoi v ramkakh deistvuyushchei Territorial'noi programmy obyazatel'nogo meditsinskogo strakhovaniya grazhdan Rossiiskoi Federatsii v Sankt-Peterburge na 2013 g. (Applications to the General Agreement on Tariffs for Medical Care (Health Services) and the Terms of Payment for Medical Care Provided in the Framework of the Existing Territorial Program of Compulsory Health Insurance for Citizens of the Russian Federation in St. Petersburg in 2013). Available at: www.spboms.ru

25. Standart pervichnoi mediko-sanitarnoi pomoshchi pri pnevmonii. Prilozhenie k prikazu Ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 20 dekabrya 2012 g. № 1213n [Standard Primary Care for Pneumonia. Annex to the Order of the Ministry of Health of the Russian Federation # 1213n dated December 20, 2012].

26. Standart meditsinskoi pomoshchi bol'nym srednim otitom. Prilozhenie k prikazu Ministerstva zdravookhraneniya i sotsial'nogo razvitiya Rossiiskoi Federatsii ot 29 noyabrya 2004 g. № 292 [The Standard of Care to Patients Otitis Media. Annex to the Order of the Ministry of Health and Social Development of the Russian Federation # 292 dated November 29, 2004].

27. World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization. 2001.

28. Rudakova A.V., Uskov A.N., Kharit S.M., Sidorenko S.V. Pharmacoeconomic aspects of pneumococcal vaccination of children in Russia. Zhurn. infektol. = Infectology journal. 2011; 3 (4): 78–83.

29. van Hoek A.J., Andrews N., Waight P.A., Miller G. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE. 2012; 7 (7): 39150. Doi:10.1371/journal.pone.0039150.